Clearside Biomedical (STU:CLM0) Total Payout Ratio: 0.05 (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CLM0 Clearside Biomedical Inc STU:CLM0
44 GF Score
Price €4.35
GF Value €108.14
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical Total Payout Ratio?

Clearside Biomedical STU:CLM0 44 Total Payout Ratio is 0.05 as of Sep. 03, 2026. GuruFocus rates STU:CLM0 with a GF Score™ of 44/100 and a GF Value™ of €108.14. The stock has 7 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Clearside Biomedical's current Total Payout Ratio is 0.05.


Clearside Biomedical Total Payout Ratio Related Terms


Clearside Biomedical Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Clearside Biomedical's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearside Biomedical Total Payout Ratio Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 -61.88 0.02 0.05 0.48

Clearside Biomedical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.05 0.22 0.00

STU:CLM0 vs CDT, BPTH, ABPO: Total Payout Ratio Comparison

For the Biotechnology subindustry, Clearside Biomedical's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Total Payout Ratio falls into.


STU:CLM0
44GF Score
Clearside Biomedical Inc STU:CLM0
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearside Biomedical Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Clearside Biomedical's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 15.651 + 0) / -32.806
=0.48

Clearside Biomedical's Total Payout Ratio for the quarter that ended in Sep. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -5.088
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.05 mean?
Clearside Biomedical (STU:CLM0) has a Total Payout Ratio of 0.05 as of Sep. 03, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Clearside Biomedical and its competitors.
Is Clearside Biomedical's Total Payout Ratio too high?
Clearside Biomedical's current Total Payout Ratio is 0.05. Overall, Clearside Biomedical has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Total Payout Ratio compare to CDT and BPTH?
Clearside Biomedical's Total Payout Ratio of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current Total Payout Ratio is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Clearside Biomedical (STU:CLM0) has a current Total Payout Ratio of 0.05. The stock's GF Value™ is €108.14, compared to a current price of €4.35 — trading 96% below its estimated fair value. The current Total Payout Ratio is 0.05. Clearside Biomedical's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Clearside Biomedical (STU:CLM0), the current Total Payout Ratio is 0.05 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €108.14.

Key valuation signals for STU:CLM0:

  • Total Payout Ratio: 0.05
  • GF Value™: €108.14 vs. price of €4.35 (96% below fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clearside Biomedical Business Description

Other Exchanges CLSDQ:USA
Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
44GF Score

Get the complete analysis for STU:CLM0

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.35
Price
€108.14
GF Value